• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NONMEM的应用经验:苯妥英钠常规临床药代动力学数据分析

Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.

作者信息

Sheiner L B, Grasela T H

出版信息

Drug Metab Rev. 1984;15(1-2):293-303. doi: 10.3109/03602538409015067.

DOI:10.3109/03602538409015067
PMID:6547663
Abstract

NONMEM, a program package the produces the extended least squares estimates of population parameters for a nonlinear mixed-effect model, has been applied to two data sets from patients routinely receiving phenytoin. A general model for the data is proposed. The models used in previous, standard-method analyses of each data set are compared to the general model using NONMEM. The comparison involves two questions: The first asks whether the parameters estimated previously agree with NONMEM estimates when the original model is used. We find that for fixed-effect parameters they generally do, while for interindividual random-effect parameters the previous methods' estimates appear upward biased relative to NONMEM. Second, the original model per se is compared to the general model by comparing the best fit to each. The general model is clearly superior. NONMEM's ability to distinguish among models, and to precisely estimate their parameters from sparse individual data, is illustrated and verified.

摘要

NONMEM是一个程序包,用于生成非线性混合效应模型总体参数的扩展最小二乘估计值,已应用于常规接受苯妥英治疗患者的两个数据集。提出了一个适用于这些数据的通用模型。将之前对每个数据集进行标准方法分析时使用的模型与使用NONMEM的通用模型进行比较。该比较涉及两个问题:第一个问题是,当使用原始模型时,之前估计的参数是否与NONMEM估计值一致。我们发现,对于固定效应参数,通常是一致的,而对于个体间随机效应参数,之前方法的估计值相对于NONMEM似乎存在向上偏差。第二个问题是,通过比较各自的最佳拟合情况,将原始模型本身与通用模型进行比较。通用模型明显更优。展示并验证了NONMEM区分模型以及从稀疏个体数据精确估计其参数的能力。

相似文献

1
Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.NONMEM的应用经验:苯妥英钠常规临床药代动力学数据分析
Drug Metab Rev. 1984;15(1-2):293-303. doi: 10.3109/03602538409015067.
2
An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.一种基于扩展非线性最小二乘法的微机分析程序MULTI(ELS)。
J Pharmacobiodyn. 1986 Feb;9(2):161-73.
3
Experiences in the application of NONMEM to pharmacokinetic data analysis.NONMEM在药代动力学数据分析中的应用经验。
Drug Metab Rev. 1984;15(1-2):317-39. doi: 10.3109/03602538409015069.
4
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.群体药代动力学参数估计的替代方法:与非线性混合效应模型的比较。
Drug Metab Rev. 1984;15(1-2):265-92. doi: 10.3109/03602538409015066.
5
Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.Perl 语言的 NONMEM 工具(PsN)——一个用于 NONMEM 相关编程的 Perl 模块。
Comput Methods Programs Biomed. 2004 Aug;75(2):85-94. doi: 10.1016/j.cmpb.2003.11.003.
6
Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.两种群体药代动力学程序NONMEM和P-PHARM用于他克莫司的比较。
Eur J Clin Pharmacol. 2002 Dec;58(9):597-605. doi: 10.1007/s00228-002-0517-7. Epub 2002 Nov 15.
7
Population pharmacokinetic data and parameter estimation based on their first two statistical moments.基于前两个统计矩的群体药代动力学数据和参数估计。
Drug Metab Rev. 1984;15(1-2):173-93. doi: 10.3109/03602538409015064.
8
Experience with NONMEM: analysis of serum concentration data in patients treated with mexiletine and lidocaine.NONMEM经验:美西律和利多卡因治疗患者血清浓度数据分析
Drug Metab Rev. 1984;15(1-2):305-15. doi: 10.3109/03602538409015068.
9
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.低剂量阿霉素及其代谢产物在艾滋病相关卡波西肉瘤患者中的药代动力学
Cancer Chemother Pharmacol. 2005 May;55(5):488-96. doi: 10.1007/s00280-004-0900-4. Epub 2005 Feb 23.
10
A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.一种用于非线性混合效应模型估计的两步迭代算法及其在群体药代动力学中的评估。
J Biopharm Stat. 1995 Jul;5(2):141-58. doi: 10.1080/10543409508835104.

引用本文的文献

1
Mathematical Models in the Description of Pregnane X Receptor (PXR)-Regulated Cytochrome P450 Enzyme Induction. pregnane X 受体 (PXR) 调控的细胞色素 P450 酶诱导的数学模型。
Int J Mol Sci. 2018 Jun 15;19(6):1785. doi: 10.3390/ijms19061785.
2
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.一项II期试点试验,旨在诱导性血液期疟疾感染研究中评估非诺喹对抗早期恶性疟原虫的安全性和有效性。
Malar J. 2016 Sep 13;15(1):469. doi: 10.1186/s12936-016-1511-3.
3
Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.
建立利福平诱导的 CYP3A4 激活动力学模型,用于从体外数据预测临床药物相互作用。
PLoS One. 2013 Sep 24;8(9):e70330. doi: 10.1371/journal.pone.0070330. eCollection 2013.
4
Performance in population models for count data, part I: maximum likelihood approximations.计数数据总体模型中的性能,第一部分:最大似然近似。
J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):353-66. doi: 10.1007/s10928-009-9126-8. Epub 2009 Aug 4.
5
Population pharmacokinetics. Theory and clinical application.群体药代动力学。理论与临床应用。
Clin Pharmacokinet. 1986 Sep-Oct;11(5):387-401. doi: 10.2165/00003088-198611050-00004.